Importance of minimal residual disease testing during the second year of therapy for children with acute lymphoblastic leukemia

Journal of Clinical Oncology

Volumn 21, Issue 4, 2003, Pages 704-709

  Marshall, Glenn M ^a   Haber, Michelle ^a   Kwan, Edward ^a   Zhu, Ling ^a   Ferrara, Daniella ^a   Xue, Chengyuan ^a   Brisco, Michael J ^a   Sykes, Pamela J ^a   Morley, Alexander ^a   Webster, Boyd ^a   Dalla Pozza, Luciano ^a   Waters, Keith ^a   Norris, Murray D ^a  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; LYMPHOCYTE ANTIGEN RECEPTOR;

ACCURACY; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BONE MARROW; CANCER CHEMOTHERAPY; CANCER RELAPSE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; GENE REARRANGEMENT; HUMAN; INFANT; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MOLECULAR CLONING; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; TREATMENT DURATION; UNIVARIATE ANALYSIS; ACUTE LYMPHOCYTIC LEUKEMIA; CHILD; DISEASE FREE SURVIVAL; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC AGENTS; BONE MARROW; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; HUMANS; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE; NEOPLASM, RESIDUAL; RANDOMIZED CONTROLLED TRIALS;

EID: 0037441844     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.10.080     Document Type: Article

References (21)

1. Rivera GK, Pinkel D, Simone JV, et al: Treatment of acute lymphoblastic leukemia: 30 years' experience at St. Jude Children's Research Hospital. N Engl J Med 329:1289-1295, 1993
2. Pui CH, Evans WE: Acute lymphoblastic leukemia. N Engl J Med 339:605-615, 1998
3. Smith M, Arthur D, Camitta B, et al: Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 14:18-24, 1996
4. Brisco MJ, Condon J, Hughes E, et al: Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction. Lancet 343:196-200, 1994
5. Cave H, van der Werff ten Bosch J, Suciu S, et al: Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer-Childhood Leukemia Cooperative Group. N Engl J Med 339:591-598, 1998
6. van Dongen JJM, Seriu T, Panzergrumayer ER, et al: Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 352:1731-1738, 1998
7. Winick N, Shuster JJ, Bowman WP, et al: Intensive oral methotrexate protects against lymphoid marrow relapse in childhood B-precursor acute lymphoblastic leukemia. J Clin Oncol 14:2803-2811, 1996
8. Mattano LA, Sather HN, Trigg ME, et al: Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: A report from the Children's Cancer Group. J Clin Oncol 18:3262-3272, 2000
9. Cave H, Guidal C, Rohrlich P, et al: Prospective monitoring and quantitation of residual blasts in childhood acute lymphoblastic leukemia by polymerase chain reaction study of delta and gamma T-cell receptor genes. Blood 83:1892-1902, 1994
10. Nizet Y, Vandaele S, Lewalle P, et al: Long-term follow-up of residual disease in acute lymphoblastic leukemia patients in complete remission using clonogeneic IgH probes and the polymerase chain reaction. Blood 82:1618-1625, 1993
11. Goulden NJ, Knechtli CJ, Garland RJ, et al: Minimal residual disease analysis for the prediction of relapse in children with standard-risk acute lymphoblastic leukaemia. Br J Haematol 100:235-244, 1998
12. Roberts WM, Estrov Z, Ouspenskaia MV, et al: Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia. N Engl J Med 336:317-323, 1997
13. Arico M, Valsecchi MG, Camitta B, et al: Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 342:998-1006, 2000
14. Nachman J, Sather H, Sensel M, et al: Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med 338:1663-1671, 1998
15. Waters K: Australian and New Zealand trials in acute lymphoblastic leukemia of childhood. Int J Pediat Haem/Oncol 5:187-197, 1998
16. Norris MD, Kwan E, Haber M, et al: Detection of evolving immunoglobulin heavy-chain gene rearrangements in acute lymphoblastic leukemia: A PCR-based assay employing overlapping DJH primers. Leukemia 9:1779-1782, 1995
17. Brisco MJ, Condon J, Sykes PJ, et al: Detection and quantitation of neoplastic cells in acute lymphoblastic leukaemia, by use of the polymerase chain reaction. Br J Haematol 79:211-217, 1991
18. Kwan E, Norris MD, Zhu L, et al: Simultaneous detection and quantitation of minimal residual disease in childhood acute lymphoblastic leukaemia using real-time polymerase chain reaction. Br J Haematol 109:430-434, 2000
19. Gaynon PS, Desai AA, Bostrom BC, et al: Early response to therapy and outcome in childhood acute lymphoblastic leukemia: a review. Cancer 80:1717-1726, 1997
20. Goulden N, Oakhill A, Steward C: Practical application of minimal residual disease assessment in childhood acute lymphoblastic leukaemia. Br J Haematol 112:275-281, 2001
21. Chessells JM: The management of high-risk lymphoblastic leukaemia in children. Br J Haematol 108:204-216, 2000